Coronavirus Notebook: China Focuses On Antivirals As Death Toll Passes SARS
Drugs Put At Center Of Fight
Chief executives of two antiviral and vaccine developers share with Scrip their development plans and projections as the death toll from the coronavirus outbreak reaches 900 with more cases being confirmed worldwide.
You may also be interested in...
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Founded five years ago, Shanghai-based Ark Bio sees big potential in the less crowded pediatric antiviral treatment market. Now the start-up is in Phase II development for its lead asset ziresovir for respiratory syncytial virus (RSV) infection, which was licensed from Roche.
Touting its coronavirus vaccines as a "global public good", China is quietly preparing for the first general approvals and launches, possibly within weeks, developers say. But who will be first in line to receive them? And at what cost? Distribution and pricing are just some of the unanswered questions.